More than 10 companies in the field of anesthesia, "Shu more sodium glucan", competed for the top spot.

Shumore sodium, known as the field of anesthesia for nearly 20 years of major drug discovery, since the market, has grown into a bomb-heavy grade drug.
by virtue of certain technical barriers (40 hand centers), as well as the particularity of the fine hemp drug, the domestic market in addition to the original research varieties approved imports, although there are more than ten enterprises on the species registered to declare, but has not yet approved domestic varieties.
at the same time, in the direction of innovative drugs, the highest development status of similar innovative varieties in China has entered the clinical phase II, I believe that soon, the direction of drug imitation and innovative varieties will be better used in domestic clinical.
the first selective myose antagonist: sodium sodium sautrose, is the first and currently the only selective myose antagonist on the market, the mechanism of which is not by inhibiting acetylcholinesterase and the mechanism of neuromuscular blocking recovery agent.
Discovery is organon Biosciences, which is developed by MSD and was first listed in July 2008 (EMA) and then approved in Japan/US/China in 2010/2015/2017;
Figure 1.1 The chemical structure of sodium sodium sautrose (2 forms) and 40 hand centers (Picture Source: ) The species has grown into a bomb shell drug since its launch! Sales have continued to rise and grow rapidly over the past five years, reaching $1,131 million in 2019.
Insight database shows that the domestic approved original research variety Brittin, the winning bid price for the last 3 years are 1380 yuan per branch.
Figure 1.2: Sodium Sodium Sautrose and Global Sales In the last 5 years To address the needs of clinical unmet ness From a clinical indication, the clinical use of sodium sautrose is mainly "targeted" muscle pine drug Rocum bromonama and Viku bromine ammonium, both varieties for the amino steroid competitive neuromuscular blocking drug (an important helper for the success of all hemp surgery), clinical use of tracheal tube intubation tube and the provision of systemic anesthesia.
clinical, according to each patient's response to adjust the dose of neuromuscular blockers, overdose has certain side effects and dangers, so the clinical urgent need for the above two varieties of "antidote", but the listing of the new, to a certain extent can alleviate the above problems, but there is a certain risk of adverse reactions;
at the same time, sodium sodium sutrose will be more applicable to the following patients: 1) difficult airways, especially in the case of "cannot intubate can not oxygenate", 2) children's medication, mostly concentrated in 2 years and older, 3) special maternal population, clinical use of sodium sodium sutrose more than 10 years, and animal test model sodium no malformation; 4) periactive respiratory function is not complete patients.
Table 2.1: MSD Company has completed Phase III Clinical Trials (NCT Statistics) Domestic innovative varieties of similar indications Development Status Domestic, selective myosemaan antagonists are relatively niche, the degree of heat is far less than the development of drugs in the field of tumor, metabolism, immunity.
relatively noteworthy is omexone sodium in the clinical phase II phase, which also reverses neuromuscular blocking induced by or vicku bromine ammonium.
the variety was jointly developed by Zhejiang Xianyu Pharmaceuticals and Hangzhou Omer Pharmaceuticals, and was the first self-developed targeted muscle pine agent in China, supported by the "12th Five-Year Plan" and "13th Five-Year Plan" National "Major New Drug Creation";
if the variety is listed, I believe it will form the most direct market competition with Sodium Su-Sodium Shuer.
Collum, Hengrui, Qilu and other 11 enterprises listed in the domestic first to Shumore sodium sodium registration of the enterprise is the Netherlands Ocanong, for clinical applications;
Figure 3.1: Shumore sodium glucan domestic registration important point in time (data from Insight database) in chronological order, the domestic registration of the first 2 domestic registration declaration, respectively, Jiangsu Hengrui, Shijiazhuang Zhiheng Pharmaceutical, are registered to chemical drugs 3.1 class declaration.
and the third Hunan Collum, is the new registration requirements of the four types of generic declaration, and then, Yangzijiang, Zhengda Tianqing, Shanghai Huilun, Jiangsu Hengrui, Guangdong Xingyu, Qilu Pharmaceuticals, Chengdu Yuandong Bio, Guizhou Yiyi Pharmaceutical, Jiangsu Yuexing Pharmaceutical, are registered with 4 types of generic declaration.
here is worth saying that the earliest registration of the variety of Jiangsu Hengrui, again with 4 drugs registered declaration, enough to see the persistence of the variety.
table 3.1 Shu more glucose sodium and domestic registration declaration representative acceptance number summary summary, that is, for the selective myosaananananas Shu more glucose sodium drug situation, and domestic innovation and imitation of the progress of the competition status.
the field of innovative varieties is relatively unique, Omekesson sodium in the domestic market did not encounter a strong innovation rival.
and imitation varieties, the competition is relatively fierce, most of them are domestic large pharmaceutical companies, strong and products throughout the country, so who's the first to be approved for listing, the market behind the market will be rich, and the price of imported drugs will also be subject to strong competition.
but whether it is the early approval of innovative varieties, or the rapid listing of imitation varieties, the ultimate beneficiaries will be domestic surgical patients, this is the most important!